Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
about
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyEpigenetic polypharmacology: from combination therapy to multitargeted drugsHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyThe sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityCombined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cellsDNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Screening of potential molecular targets for colorectal cancer therapy.Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii.Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, VorinostatThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsThe dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsBH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibitionTherapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.Recently identified and potential targets for colon cancer treatment.Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.Endoplasmic reticulum stress, unfolded protein response and development of colon adenocarcinoma.
P2860
Q26746038-B0CEACB8-2CE8-42A4-A4E7-E26D87C76870Q28067666-C5C1C7AA-9528-4160-8661-7259F09DF344Q28082536-C1A26553-C057-4D87-8284-1D1C56697B9EQ28487756-F6F25870-FB48-4F9E-B44B-02314BF5C73CQ30409676-0B635931-F04D-49DA-914A-072465D9F3ACQ30931932-FC24AE8F-34DD-4A0C-9826-127770E8AD1BQ33735051-B7E376AB-2B27-4086-87E4-9E14CA04D555Q33740964-27AC346C-6582-4655-9E1D-AC041CAAFCF7Q34213967-F5C03A50-4C91-400B-BA25-9DF5C3A40862Q34218976-A0023500-002A-46D1-85A3-D9BEB5E83555Q35055207-94D02A45-7F90-4647-81EF-6537AC047C5EQ36438027-D5C9D9A9-A4FC-4F94-A403-4A631E049529Q37017342-26C88D2D-688A-40D2-8CF5-0233DD80E997Q37077410-B5B3C955-3365-4358-B78C-CCE71FC379FBQ37301751-75D08DD8-4BA2-473E-8660-3999A470D0CAQ37400663-7BB4E7A4-E7D4-470C-8D31-7C27C880BD5DQ37421431-97D1F024-B2C3-4F77-AFD4-47CEE7BCEA6DQ37596249-DD0CBF32-B92D-4A67-B234-F3C1CD40D47CQ37763104-EEA675A2-D244-4906-91C5-70C52F78B70FQ38002127-682E7F3B-07FB-42DD-81D8-A471FF5FE1DDQ38674753-148DDD5B-F215-4EE2-861C-CBB6E86C4557Q38887964-77948AA4-105B-4752-B3A2-AA31C6630E34Q38962956-FED0FD67-2EC7-46CF-9976-31FD8B0FA4D6Q39274612-FAF15D4A-2FF4-45AE-A9DB-515F93B32A5AQ42738022-C2E1A258-705E-40FC-8368-A5FE6FB4294CQ44633880-1C919F69-7E4D-408F-A80E-BED9F855C96FQ47240693-AABCD12C-EF2E-4718-AD44-69E15BB34554Q47789045-44723E02-FF0B-468F-A1F6-10B47A3954F5
P2860
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@ast
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@en
type
label
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@ast
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@en
prefLabel
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@ast
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@en
P2093
P2860
P1476
Vorinostat and bortezomib exer ...... ts in colon cancer cell models
@en
P2093
John J Tentler
Mark Morrow
S Gail Eckhardt
Sara A Kaufman
Todd M Pitts
P2860
P304
P356
10.1158/1535-7163.MCT-08-0534
P577
2009-01-27T00:00:00Z